Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relapsed AML 2001/01
NL-OMON20351Phase 3Active, not recruiting
- Sponsor
- Dutch Childhood Oncology Group
- Start
- Jan 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daunorubicin in acute myeloid leukemia (AML), sponsored by Dutch Childhood Oncology Group. Primary endpoint: Bone marrow blast response after course I. Started Jan 2001; status: active, not recruiting.
02
Drugs
daunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON20351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20351.